ZANDER, AXEL ROLF,AYUKETANG, FRANCIS AYUK,RICHTER, WOLFGANG,WEBER, LUTZ
申请号：
CA2673040
公开号：
CA2673040C
申请日:
2007.11.09
申请国别(地区):
CA
年份:
2016
代理人:
摘要：
Use of a tri-substituted glycerol compound is described for the treatment ofhematologicalmalignancies. In particular, the present invention relates to the use of a tri-substituted glycerolcompound according to formula (I)(see formula I)or an enantiomer or diastereomer or a pharmaceutically acceptable salt thereofand at least onepharmaceutically acceptable excipient, whereinX is selected from the group consisting of phosphate and sulfate；R1 is selected from the group consisting of C16- C20 alkyl；R2 is selected from the group consisting of C1 -C3 alkyl and C1 -C3hydroxyalkyl；R3 is selected from the group consisting of hydrogen and C1-C3 alkyl；R4 is selected from the group consisting of C1-C3 alkylene and C3-C6cycloalkylene； andR5 is selected from the group consisting of hydrogen and methyl,and wherein the medicament is a pharmaceutical solid dosage form for oraladministration and isused in combination with at least one other pharmaceutical comprising one ormore additionalactive ingredient/s which is/are selected from the group consisting ofantimetabolites, plantalkaloides, inhibitors of topoisomersase I and proteasome inhibitors. Kitscomprising suchcompounds are further described. As well, an in vitro method for determiningthe susceptibilityof such malignant cells to a medicament as defined in the invention isdescribed.
